<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	>

<channel>
	<title>PR Hub &#187; Health Care / Hospitals</title>
	<atom:link href="http://pr.gaeatimes.com/c/health/health-care-hospitals/feed/" rel="self" type="application/rss+xml" />
	<link>http://pr.gaeatimes.com</link>
	<description></description>
	<pubDate>Fri, 16 Dec 2011 13:12:07 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.7.1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>New Roche Screening Test for Abacavir Hypersensitivity Available in Europe</title>
		<link>http://pr.gaeatimes.com/new-roche-screening-test-for-abacavir-hypersensitivity-available-in-europe-54940/</link>
		<comments>http://pr.gaeatimes.com/new-roche-screening-test-for-abacavir-hypersensitivity-available-in-europe-54940/#comments</comments>
		<pubDate>Fri, 16 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Roche</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[california]]></category>

		<category><![CDATA[December 16]]></category>

		<category><![CDATA[Pleasanton]]></category>

		<category><![CDATA[Roche]]></category>

		<category><![CDATA[Western Europe]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/new-roche-screening-test-for-abacavir-hypersensitivity-available-in-europe-54940/</guid>
		<description><![CDATA[PLEASANTON, California, December 16, 2011  -

- The test confidently detects HLA-B*5701 to help decrease risk of abacavir hypersensitivity reaction
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its HLA-B*5701 screening test[1] is now commercially available in Europe. HLA-B*5701 screening provides physicians with a means to avoid prescribing drugs to patients at high risk of ... <a href="http://pr.gaeatimes.com/new-roche-screening-test-for-abacavir-hypersensitivity-available-in-europe-54940/">Original source on Gaea Times at  : New Roche Screening Test for Abacavir Hypersensitivity Available in Europe</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/new-roche-screening-test-for-abacavir-hypersensitivity-available-in-europe-54940/feed/</wfw:commentRss>
		</item>
		<item>
		<title>ThromboGenics and BioInvent Complete Enrollment of Phase IIb Trial With TB-402 Ahead of Schedule</title>
		<link>http://pr.gaeatimes.com/thrombogenics-and-bioinvent-complete-enrollment-of-phase-iib-trial-with-tb-402-ahead-of-schedule-54941/</link>
		<comments>http://pr.gaeatimes.com/thrombogenics-and-bioinvent-complete-enrollment-of-phase-iib-trial-with-tb-402-ahead-of-schedule-54941/#comments</comments>
		<pubDate>Fri, 16 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Thrombogenics</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[belgium]]></category>

		<category><![CDATA[Belgium And Lund]]></category>

		<category><![CDATA[December 16]]></category>

		<category><![CDATA[Leuven]]></category>

		<category><![CDATA[sweden]]></category>

		<category><![CDATA[Thrombogenics]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/thrombogenics-and-bioinvent-complete-enrollment-of-phase-iib-trial-with-tb-402-ahead-of-schedule-54941/</guid>
		<description><![CDATA[LEUVEN, Belgium and LUND, Sweden, December 16, 2011  -

ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that they have completed the enrolment of a 632-patient Phase IIb trial with their novel long-acting anticoagulant TB-402 (factor VIII inhibitor) for the prophylaxis of venous thromboembolism (VTE) after total hip surgery. .... <a href="http://pr.gaeatimes.com/thrombogenics-and-bioinvent-complete-enrollment-of-phase-iib-trial-with-tb-402-ahead-of-schedule-54941/" title="ThromboGenics and BioInvent Complete Enrollment of Phase IIb Trial With TB-402 Ahead of Schedule">Source &nbsp;: Gaea News Network</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/thrombogenics-and-bioinvent-complete-enrollment-of-phase-iib-trial-with-tb-402-ahead-of-schedule-54941/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Ranbaxy Global Consumer Healthcare &amp; Aanjaneya Lifecare Declared Winners In &#34;Neutraceutical Segments&#34; &amp; &#34;Company Of The Year Award&#34; Respectively at 4th Annual Pharmaceutical Leadership Awards 2011</title>
		<link>http://pr.gaeatimes.com/ranbaxy-global-consumer-healthcare-aanjaneya-lifecare-declared-winners-in-neutraceutical-segments-company-of-the-year-award-respectively-at-4th-annual-pharmaceutica-54945/</link>
		<comments>http://pr.gaeatimes.com/ranbaxy-global-consumer-healthcare-aanjaneya-lifecare-declared-winners-in-neutraceutical-segments-company-of-the-year-award-respectively-at-4th-annual-pharmaceutica-54945/#comments</comments>
		<pubDate>Fri, 16 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Pharma Leaders</dc:creator>
		
		<category><![CDATA[Awards]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Personnel Announcements]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[December 16]]></category>

		<category><![CDATA[India]]></category>

		<category><![CDATA[Mumbai]]></category>

		<category><![CDATA[Pharma Leaders]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/ranbaxy-global-consumer-healthcare-aanjaneya-lifecare-declared-winners-in-neutraceutical-segments-company-of-the-year-award-respectively-at-4th-annual-pharmaceutica-54945/</guid>
		<description><![CDATA[MUMBAI, India, December 16, 2011  -

Kewal Handa of Pfizer &#38; Aditi Kare of Indoco are Business Leaders While Pfizer, Abbott, GSK, Microlabs, Elder Pharmaceuticals, Fortis, Bharat Biotech, Adriot are Winners
The 4th Annual Pharmaceutical Leadership Summit &#38; Awards 2011 (www.pharmasummit.in ),  organized by India&#8217;s leading bi-monthly Pharma Magazine (www.pharmaleaders.co.in ) &#38; the IACC, ended on .... <a href="http://pr.gaeatimes.com/ranbaxy-global-consumer-healthcare-aanjaneya-lifecare-declared-winners-in-neutraceutical-segments-company-of-the-year-award-respectively-at-4th-annual-pharmaceutica-54945/" title="Ranbaxy Global Consumer Healthcare &amp; Aanjaneya Lifecare Declared Winners In &quot;Neutraceutical Segments&quot; &amp; &quot;Company Of The Year Award&quot; Respectively at 4th Annual Pharmaceutical Leadership Awards 2011">Source &nbsp;: Gaea News Network</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/ranbaxy-global-consumer-healthcare-aanjaneya-lifecare-declared-winners-in-neutraceutical-segments-company-of-the-year-award-respectively-at-4th-annual-pharmaceutica-54945/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Hospital Operating Rooms are now Optimized in Real-time With a Joint Solution From Karl Storz and Ekahau</title>
		<link>http://pr.gaeatimes.com/hospital-operating-rooms-are-now-optimized-in-real-time-with-a-joint-solution-from-karl-storz-and-ekahau-54950/</link>
		<comments>http://pr.gaeatimes.com/hospital-operating-rooms-are-now-optimized-in-real-time-with-a-joint-solution-from-karl-storz-and-ekahau-54950/#comments</comments>
		<pubDate>Fri, 16 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Ekahau</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Investors]]></category>

		<category><![CDATA[Joint Ventures]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[December 16]]></category>

		<category><![CDATA[Ekahau]]></category>

		<category><![CDATA[Reston]]></category>

		<category><![CDATA[virginia]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/hospital-operating-rooms-are-now-optimized-in-real-time-with-a-joint-solution-from-karl-storz-and-ekahau-54950/</guid>
		<description><![CDATA[RESTON, Virginia, December 16, 2011  -

Ekahau Inc. the leading global provider of high performance Wi-Fi-based Real-Time Location Systems (RTLS), and KARL STORZ GmbH &#38; Co. KG, the endoscopy specialist, announced today a joint solution for OR management. The MIC Clinic in Berlin has successfully deployed and is using the combined solution of Karl Storz .... Source article &nbsp;: <a href="http://pr.gaeatimes.com/hospital-operating-rooms-are-now-optimized-in-real-time-with-a-joint-solution-from-karl-storz-and-ekahau-54950/">Hospital Operating Rooms are now Optimized in Real-time With a Joint Solution From Karl Storz and Ekahau</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/hospital-operating-rooms-are-now-optimized-in-real-time-with-a-joint-solution-from-karl-storz-and-ekahau-54950/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Genome Sequencing Assists Research into Major Public Diseases in France.</title>
		<link>http://pr.gaeatimes.com/genome-sequencing-assists-research-into-major-public-diseases-in-france-54955/</link>
		<comments>http://pr.gaeatimes.com/genome-sequencing-assists-research-into-major-public-diseases-in-france-54955/#comments</comments>
		<pubDate>Fri, 16 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Life Technologies Corporation</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Surveys / Polls / Research]]></category>

		<category><![CDATA[December 16]]></category>

		<category><![CDATA[Facebook]]></category>

		<category><![CDATA[France]]></category>

		<category><![CDATA[Glasgow]]></category>

		<category><![CDATA[life technologies corporation]]></category>

		<category><![CDATA[scotland]]></category>

		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/genome-sequencing-assists-research-into-major-public-diseases-in-france-54955/</guid>
		<description><![CDATA[GLASGOW, Scotland, December 16, 2011  -


- University of Strasbourg adopts Life Technologies&#8217; SOLiD&#8482; sequencing platform to gain insight into diabetes, obesity, asthma, arterial hypertension and other common diseases.
Life Technologies Corporation (NASDAQ:LIFE) announced that its instruments are supporting the 1.1 million Euro Genomax project at the Haematology and Immunology Research Centre led by Professor Seiamak .... <a href="http://pr.gaeatimes.com/genome-sequencing-assists-research-into-major-public-diseases-in-france-54955/" title="Genome Sequencing Assists Research into Major Public Diseases in France.">Source &nbsp;: Gaea News Network</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/genome-sequencing-assists-research-into-major-public-diseases-in-france-54955/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Health Robotics Continues Worldwide Expansion in Denmark With 2nd Generation Robots and Novamed</title>
		<link>http://pr.gaeatimes.com/health-robotics-continues-worldwide-expansion-in-denmark-with-2nd-generation-robots-and-novamed-54970/</link>
		<comments>http://pr.gaeatimes.com/health-robotics-continues-worldwide-expansion-in-denmark-with-2nd-generation-robots-and-novamed-54970/#comments</comments>
		<pubDate>Fri, 16 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Health Robotics</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Bozen]]></category>

		<category><![CDATA[December 16]]></category>

		<category><![CDATA[Health Robotics]]></category>

		<category><![CDATA[Italy]]></category>

		<category><![CDATA[Sud-tirol]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/health-robotics-continues-worldwide-expansion-in-denmark-with-2nd-generation-robots-and-novamed-54970/</guid>
		<description><![CDATA[BOZEN, Sud-Tirol, Italy, December 16, 2011  -

After successfully switching marketing channel strategies from certain non-performing indirect distribution channels in several countries to Health Robotics&#8217; direct management in 1Q2011, the company today announced the extension of the same control over local operations in Denmark, in partnership with local Oncology leader Novamed.
Ulrich R. Andersen, Novamed&#8217;s Managing .... <a href="http://pr.gaeatimes.com/health-robotics-continues-worldwide-expansion-in-denmark-with-2nd-generation-robots-and-novamed-54970/">Source &nbsp;: Health Robotics Continues Worldwide Expansion in Denmark With 2nd Generation Robots and Novamed</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/health-robotics-continues-worldwide-expansion-in-denmark-with-2nd-generation-robots-and-novamed-54970/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Amsterdam Molecular Therapeutics Announces Negative Equity Position</title>
		<link>http://pr.gaeatimes.com/amsterdam-molecular-therapeutics-announces-negative-equity-position-54868/</link>
		<comments>http://pr.gaeatimes.com/amsterdam-molecular-therapeutics-announces-negative-equity-position-54868/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Amsterdam Molecular Therapeutics amt B.v</dc:creator>
		
		<category><![CDATA[Banking and Financial Services]]></category>

		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Financing Agreements]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Amsterdam]]></category>

		<category><![CDATA[Amsterdam Molecular Therapeutics (amt) B.v]]></category>

		<category><![CDATA[December 15]]></category>

		<category><![CDATA[Netherlands]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/amsterdam-molecular-therapeutics-announces-negative-equity-position-54868/</guid>
		<description><![CDATA[AMSTERDAM, December 15, 2011  -

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the Company has a negative equity position, as a result of ongoing loss-making operations. The development of this negative equity position is in line with previous guidance that the Company has cash into ... Read more <a href="http://pr.gaeatimes.com/amsterdam-molecular-therapeutics-announces-negative-equity-position-54868/" title="Amsterdam Molecular Therapeutics Announces Negative Equity Position">&raquo;&raquo;&raquo;</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/amsterdam-molecular-therapeutics-announces-negative-equity-position-54868/feed/</wfw:commentRss>
		</item>
		<item>
		<title>ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012</title>
		<link>http://pr.gaeatimes.com/reprocell-licensed-commercialization-right-on-human-ips-cell-derived-hepatocytes-expected-launch-in-q2-2012-54873/</link>
		<comments>http://pr.gaeatimes.com/reprocell-licensed-commercialization-right-on-human-ips-cell-derived-hepatocytes-expected-launch-in-q2-2012-54873/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Reprocell Inc.</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Licensing / Marketing Agreements]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[December 15]]></category>

		<category><![CDATA[Japan]]></category>

		<category><![CDATA[Reprocell Inc.]]></category>

		<category><![CDATA[Yokohama]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/reprocell-licensed-commercialization-right-on-human-ips-cell-derived-hepatocytes-expected-launch-in-q2-2012-54873/</guid>
		<description><![CDATA[YOKOHAMA, Japan, December 15, 2011  -

ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today that the company licensed worldwide right to commercialize hepatocytes derived from human iPS (induced pluripotent stem) cells. ReproCELL has been collaborating with the National Institute of Biomedical Innovation (NIBIO; Director General: Koichi Yamanishi; Osaka, Japan) to establish an effective in-vitro drug  [..] <a href="http://pr.gaeatimes.com/reprocell-licensed-commercialization-right-on-human-ips-cell-derived-hepatocytes-expected-launch-in-q2-2012-54873/">Read the original article: here</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/reprocell-licensed-commercialization-right-on-human-ips-cell-derived-hepatocytes-expected-launch-in-q2-2012-54873/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Babies are Dying Needlessly in the UK Through Ignorance and Unavailability of Tests Routinely Offered in Other Western Countries</title>
		<link>http://pr.gaeatimes.com/babies-are-dying-needlessly-in-the-uk-through-ignorance-and-unavailability-of-tests-routinely-offered-in-other-western-countries-54885/</link>
		<comments>http://pr.gaeatimes.com/babies-are-dying-needlessly-in-the-uk-through-ignorance-and-unavailability-of-tests-routinely-offered-in-other-western-countries-54885/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Group B Strep Support</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Surveys / Polls / Research]]></category>

		<category><![CDATA[December 15]]></category>

		<category><![CDATA[Group B Strep Support]]></category>

		<category><![CDATA[London]]></category>

		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/babies-are-dying-needlessly-in-the-uk-through-ignorance-and-unavailability-of-tests-routinely-offered-in-other-western-countries-54885/</guid>
		<description><![CDATA[LONDON, December 15, 2011  -
A new opinion poll has found that most young women support the introduction of a national screening programme to detect Group B Strep in pregnant women.

A recent survey conducted by ComRes on behalf of Group B Strep Support demonstrated that while more than half (54%) the women aged between 20-35 .... <a href="http://pr.gaeatimes.com/babies-are-dying-needlessly-in-the-uk-through-ignorance-and-unavailability-of-tests-routinely-offered-in-other-western-countries-54885/">Read the original article &nbsp;: Babies are Dying Needlessly in the UK Through Ignorance and Unavailability of Tests Routinely Offered in Other Western Countries</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/babies-are-dying-needlessly-in-the-uk-through-ignorance-and-unavailability-of-tests-routinely-offered-in-other-western-countries-54885/feed/</wfw:commentRss>
		</item>
		<item>
		<title>World’s First Curve(TM) Image Guided Surgery System Now Operating in Germany</title>
		<link>http://pr.gaeatimes.com/world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54886/</link>
		<comments>http://pr.gaeatimes.com/world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54886/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Brainlab Ag</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Brainlab Ag]]></category>

		<category><![CDATA[December 15]]></category>

		<category><![CDATA[Germany]]></category>

		<category><![CDATA[Munich]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54886/</guid>
		<description><![CDATA[MUNICH, December 15, 2011  -
Highly advanced surgical navigation system to enable faster, more precise and safer surgery

This week, university hospital Klinikum rechts der Isar in Munich, Germany, is the first hospital in the world to operate with Brainlab&#8217;s Curve&#8482; Image Guided Surgery system. The new technology is hoped to provide surgeons with the best ... <a href="http://pr.gaeatimes.com/world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54886/">Original article on  : World’s First Curve(TM) Image Guided Surgery System Now Operating in Germany</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54886/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Amphetamobile Develops AMMO RACK App for SciVerse Applications</title>
		<link>http://pr.gaeatimes.com/amphetamobile-develops-ammo-rack-app-for-sciverse-applications-54898/</link>
		<comments>http://pr.gaeatimes.com/amphetamobile-develops-ammo-rack-app-for-sciverse-applications-54898/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Elsevier</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Media]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Amsterdam]]></category>

		<category><![CDATA[December 15]]></category>

		<category><![CDATA[Elsevier]]></category>

		<category><![CDATA[Netherlands]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/amphetamobile-develops-ammo-rack-app-for-sciverse-applications-54898/</guid>
		<description><![CDATA[AMSTERDAM, December 15, 2011  -

Researchers to save and organize content for mobile use with document management app

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the availability of the AMMO RACK app on SciVerse Applications. Developed by mobile platform developer Amphetamobile (AMMO), the application enables users to save .... <a href="http://pr.gaeatimes.com/amphetamobile-develops-ammo-rack-app-for-sciverse-applications-54898/" title="Amphetamobile Develops AMMO RACK App for SciVerse Applications">Source &nbsp;: Gaea News Network</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/amphetamobile-develops-ammo-rack-app-for-sciverse-applications-54898/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Enlight Biosciences Forms New Partnerships with AstraZeneca and Novo Nordisk</title>
		<link>http://pr.gaeatimes.com/enlight-biosciences-forms-new-partnerships-with-astrazeneca-and-novo-nordisk-54899/</link>
		<comments>http://pr.gaeatimes.com/enlight-biosciences-forms-new-partnerships-with-astrazeneca-and-novo-nordisk-54899/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Enlight Biosciences Llc</dc:creator>
		
		<category><![CDATA[Banking and Financial Services]]></category>

		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Financing Agreements]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Investors]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Venture Capital]]></category>

		<category><![CDATA[Boston]]></category>

		<category><![CDATA[December 15]]></category>

		<category><![CDATA[Enlight Biosciences Llc]]></category>

		<category><![CDATA[Massachusetts]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/enlight-biosciences-forms-new-partnerships-with-astrazeneca-and-novo-nordisk-54899/</guid>
		<description><![CDATA[BOSTON, December 15, 2011  -
Enlight Biosciences LLC announced today that it has formed new partnerships with AstraZeneca and Novo Nordisk.  As partners in Enlight, AstraZeneca and Novo Nordisk will have the opportunity to collaborate and invest in the development of potentially transformational technologies with application to their therapeutic programs.  Enlight was created by PureTech Ventures .... Source article &nbsp;: <a href="http://pr.gaeatimes.com/enlight-biosciences-forms-new-partnerships-with-astrazeneca-and-novo-nordisk-54899/">Enlight Biosciences Forms New Partnerships with AstraZeneca and Novo Nordisk</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/enlight-biosciences-forms-new-partnerships-with-astrazeneca-and-novo-nordisk-54899/feed/</wfw:commentRss>
		</item>
		<item>
		<title>QUENTIQ Names Mark B Hoffman, Former CEO of Sybase and Commerce One, President and CEO of the Newly Founded QUENTIQ Americas, Inc.</title>
		<link>http://pr.gaeatimes.com/quentiq-names-mark-b-hoffman-former-ceo-of-sybase-and-commerce-one-president-and-ceo-of-the-newly-founded-quentiq-americas-inc-54903/</link>
		<comments>http://pr.gaeatimes.com/quentiq-names-mark-b-hoffman-former-ceo-of-sybase-and-commerce-one-president-and-ceo-of-the-newly-founded-quentiq-americas-inc-54903/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Quentiq</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Computer / Electronics]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Personnel Announcements]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Technology]]></category>

		<category><![CDATA[December 15]]></category>

		<category><![CDATA[Quentiq]]></category>

		<category><![CDATA[Switzerland]]></category>

		<category><![CDATA[Zurich]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/quentiq-names-mark-b-hoffman-former-ceo-of-sybase-and-commerce-one-president-and-ceo-of-the-newly-founded-quentiq-americas-inc-54903/</guid>
		<description><![CDATA[ZURICH, December 15, 2011  -
The innovative health platform company QUENTIQ proudly announced today that former Sybase co-founder and Chief Executive Officer and Commerce One Chief Executive Officer Mark B. Hoffman will be joining the company as President and Chief Executive Officer of QUENTIQ Americas, Inc. to build the US operations. Mr. Hoffmann will also .... <a href="http://pr.gaeatimes.com/quentiq-names-mark-b-hoffman-former-ceo-of-sybase-and-commerce-one-president-and-ceo-of-the-newly-founded-quentiq-americas-inc-54903/">Source &nbsp;: QUENTIQ Names Mark B Hoffman, Former CEO of Sybase and Commerce One, President and CEO of the Newly Founded QUENTIQ Americas, Inc.</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/quentiq-names-mark-b-hoffman-former-ceo-of-sybase-and-commerce-one-president-and-ceo-of-the-newly-founded-quentiq-americas-inc-54903/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Journal of Endovascular Therapy Publishes Two-Year Data On SUPERA® Stent Used in the Superficial Femoral Artery</title>
		<link>http://pr.gaeatimes.com/journal-of-endovascular-therapy-publishes-two-year-data-on-supera%c2%ae-stent-used-in-the-superficial-femoral-artery-54909/</link>
		<comments>http://pr.gaeatimes.com/journal-of-endovascular-therapy-publishes-two-year-data-on-supera%c2%ae-stent-used-in-the-superficial-femoral-artery-54909/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Idev Technologies Incorporated</dc:creator>
		
		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Magazines]]></category>

		<category><![CDATA[Media]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[December 15]]></category>

		<category><![CDATA[Idev Technologies Incorporated]]></category>

		<category><![CDATA[texas]]></category>

		<category><![CDATA[Webster]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/journal-of-endovascular-therapy-publishes-two-year-data-on-supera%c2%ae-stent-used-in-the-superficial-femoral-artery-54909/</guid>
		<description><![CDATA[WEBSTER, Texas, December 15, 2011  -


IDEV Technologies, Inc. today announced the publication of 24-month data on the company&#8217;s SUPERA® stent.  The data was published in the December issue of the Journal of Endovascular Therapy, and includes the results of the Leipzig SUPERA Registry, which studied the use of the SUPERA interwoven nitinol stent in .... <a href="http://pr.gaeatimes.com/journal-of-endovascular-therapy-publishes-two-year-data-on-supera%c2%ae-stent-used-in-the-superficial-femoral-artery-54909/" title="Journal of Endovascular Therapy Publishes Two-Year Data On SUPERA® Stent Used in the Superficial Femoral Artery">Source &nbsp;: Gaea News Network</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/journal-of-endovascular-therapy-publishes-two-year-data-on-supera%c2%ae-stent-used-in-the-superficial-femoral-artery-54909/feed/</wfw:commentRss>
		</item>
		<item>
		<title>CORRECTION - Brainlab AG: World’s First Curve(TM) Image Guided Surgery System Now Operating in Germany</title>
		<link>http://pr.gaeatimes.com/correction-brainlab-ag-world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54935/</link>
		<comments>http://pr.gaeatimes.com/correction-brainlab-ag-world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54935/#comments</comments>
		<pubDate>Thu, 15 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Brainlab Ag</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Brainlab Ag]]></category>

		<category><![CDATA[December 15]]></category>

		<category><![CDATA[Germany]]></category>

		<category><![CDATA[Munich]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/correction-brainlab-ag-world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54935/</guid>
		<description><![CDATA[MUNICH, December 15, 2011  -
In the news release, &#8220;World&#8217;s First Curve(TM) Image Guided Surgery System Now Operating in Germany&#8221; issued on 15 Dec 2011 09:12 GMT, by Brainlab AG over PR Newswire, we are advised by a representative of the company that some minor changes were required to be made within the first paragraph .... <a href="http://pr.gaeatimes.com/correction-brainlab-ag-world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54935/">Original article on Gaea Times at  &nbsp;: CORRECTION - Brainlab AG: World’s First Curve(TM) Image Guided Surgery System Now Operating in Germany</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/correction-brainlab-ag-world%e2%80%99s-first-curvetm-image-guided-surgery-system-now-operating-in-germany-54935/feed/</wfw:commentRss>
		</item>
		<item>
		<title>A New International Congress on Regenerative Medicine Held With Great Success by Cryo-Save in Bosnia</title>
		<link>http://pr.gaeatimes.com/a-new-international-congress-on-regenerative-medicine-held-with-great-success-by-cryo-save-in-bosnia-54794/</link>
		<comments>http://pr.gaeatimes.com/a-new-international-congress-on-regenerative-medicine-held-with-great-success-by-cryo-save-in-bosnia-54794/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Cryo-save Ag</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Cryo-save Ag]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[Netherlands]]></category>

		<category><![CDATA[The Netherlands]]></category>

		<category><![CDATA[Zutphen]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/a-new-international-congress-on-regenerative-medicine-held-with-great-success-by-cryo-save-in-bosnia-54794/</guid>
		<description><![CDATA[ZUTPHEN, The Netherlands, December 14, 2011  -

It is part of Cryo-Save&#8217;s educational program deployment to increase the awareness of stem cells therapy and regenerative medicine amongst healthcare professionals.
The Second international congress &#8220;Regenerative medicine - stem cells, genetic engineering and biotechnology&#8221; was held on December 9 in Sarajevo, supported by the Institute for Genetic Engineering .... Read the original article &nbsp;: <a href="http://pr.gaeatimes.com/a-new-international-congress-on-regenerative-medicine-held-with-great-success-by-cryo-save-in-bosnia-54794/">here</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/a-new-international-congress-on-regenerative-medicine-held-with-great-success-by-cryo-save-in-bosnia-54794/feed/</wfw:commentRss>
		</item>
		<item>
		<title>THIS IS A TEST FROM PR NEWSWIRE - Please ignore</title>
		<link>http://pr.gaeatimes.com/this-is-a-test-from-pr-newswire-please-ignore-54796/</link>
		<comments>http://pr.gaeatimes.com/this-is-a-test-from-pr-newswire-please-ignore-54796/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Prn Test Tandem Unit Subs Company</dc:creator>
		
		<category><![CDATA[Banking and Financial Services]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Computer / Electronics]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Technology]]></category>

		<category><![CDATA[Telecommunications]]></category>

		<category><![CDATA[Trade Show]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[India]]></category>

		<category><![CDATA[Mumbai]]></category>

		<category><![CDATA[Prn Test Tandem Unit Subs Company]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/this-is-a-test-from-pr-newswire-please-ignore-54796/</guid>
		<description><![CDATA[MUMBAI, December 14,2011  -
Curabitur molestie mauris sed dolor dictum iaculis. Nulla sed libero felis, id viverra urna. Duis dictum, purus in condimentum tincidunt, nisl lacus porta diam, sit amet suscipit libero est sit amet dui. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris est velit, iaculis scelerisque tempus semper, eleifend ac erat. Duis ... <a href="http://pr.gaeatimes.com/this-is-a-test-from-pr-newswire-please-ignore-54796/">Original source on Gaea Times at  : THIS IS A TEST FROM PR NEWSWIRE - Please ignore</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/this-is-a-test-from-pr-newswire-please-ignore-54796/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Coloplast Makes More Products, Emits Less CO2</title>
		<link>http://pr.gaeatimes.com/coloplast-makes-more-products-emits-less-co2-54799/</link>
		<comments>http://pr.gaeatimes.com/coloplast-makes-more-products-emits-less-co2-54799/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Coloplast As</dc:creator>
		
		<category><![CDATA[Conservation / Recycling]]></category>

		<category><![CDATA[Environment]]></category>

		<category><![CDATA[Environmental Issues]]></category>

		<category><![CDATA[Government and Policy]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Coloplast A/s]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[denmark]]></category>

		<category><![CDATA[Hmlebaek]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/coloplast-makes-more-products-emits-less-co2-54799/</guid>
		<description><![CDATA[HMLEBAEK, Denmark, December 14, 2011  -

For the first time, the medical device company Coloplast sets a target for reducing its CO2 emissions from production. The goal is an absolute reduction of 10 percent* in the next three years.
To view the Multimedia News Release, please click:
multivu.prnewswire.com/mnr/prne/coloplastas/52802/
&#8220;Even though we expect an 8 percent increase in production, .... Read the original article &nbsp;: <a href="http://pr.gaeatimes.com/coloplast-makes-more-products-emits-less-co2-54799/">here</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/coloplast-makes-more-products-emits-less-co2-54799/feed/</wfw:commentRss>
		</item>
		<item>
		<title>ReportsnReports - Aseptic Packaging to 2015</title>
		<link>http://pr.gaeatimes.com/reportsnreports-aseptic-packaging-to-2015-54811/</link>
		<comments>http://pr.gaeatimes.com/reportsnreports-aseptic-packaging-to-2015-54811/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Reportsnreports</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Surveys / Polls / Research]]></category>

		<category><![CDATA[Dallas]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[Reportsnreports]]></category>

		<category><![CDATA[United States of America]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/reportsnreports-aseptic-packaging-to-2015-54811/</guid>
		<description><![CDATA[DALLAS, December 14, 2011  -
ReportsnReports adds new market research report &#8216;Aseptic Packaging to 2015&#8216; to its store. This study analyzes the $3.5 billion US aseptic packaging industry. It presents historical demand data for the years 2000, 2005 and 2010, and forecasts for 2015 and 2020 by product (e.g., plastic bottles, vials and ampuls, prefillable ... <a href="http://pr.gaeatimes.com/reportsnreports-aseptic-packaging-to-2015-54811/">Read : ReportsnReports - Aseptic Packaging to 2015</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/reportsnreports-aseptic-packaging-to-2015-54811/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Kymos, a Catalan Company, Signs a Collaboration Agreement With the Pharmaceutical Group Ipsen</title>
		<link>http://pr.gaeatimes.com/kymos-a-catalan-company-signs-a-collaboration-agreement-with-the-pharmaceutical-group-ipsen-54824/</link>
		<comments>http://pr.gaeatimes.com/kymos-a-catalan-company-signs-a-collaboration-agreement-with-the-pharmaceutical-group-ipsen-54824/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Kymos Pharma Services</dc:creator>
		
		<category><![CDATA[Contracts]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Investors]]></category>

		<category><![CDATA[Joint Ventures]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Barcelona]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[Kymos Pharma Services]]></category>

		<category><![CDATA[Spain]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/kymos-a-catalan-company-signs-a-collaboration-agreement-with-the-pharmaceutical-group-ipsen-54824/</guid>
		<description><![CDATA[BARCELONA, Spain, December 14, 2011  -

The Contract Research Organization Kymos Pharma Services -specialised in analysis for the pharmaceutical, fine chemicals, biotechnological, veterinary, cosmetic and nutraceuticals sectors- has signed an agreement with the French multinational group Ipsen to take in a team of eight scientists from Ipsen R&#38;D Centre in Sant Feliu de Llobregat (Barcelona).
For ... <a href="http://pr.gaeatimes.com/kymos-a-catalan-company-signs-a-collaboration-agreement-with-the-pharmaceutical-group-ipsen-54824/">Read this article on Gaea Times at  : Kymos, a Catalan Company, Signs a Collaboration Agreement With the Pharmaceutical Group Ipsen</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/kymos-a-catalan-company-signs-a-collaboration-agreement-with-the-pharmaceutical-group-ipsen-54824/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Visongain&#8217;s Report Predicts That Medical Biobanking Market Will Reach 19.1 Bllion Dollars in 2015</title>
		<link>http://pr.gaeatimes.com/visongains-report-predicts-that-medical-biobanking-market-will-reach-191-bllion-dollars-in-2015-54826/</link>
		<comments>http://pr.gaeatimes.com/visongains-report-predicts-that-medical-biobanking-market-will-reach-191-bllion-dollars-in-2015-54826/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Visiongain</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Surveys / Polls / Research]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[London]]></category>

		<category><![CDATA[United Kingdom]]></category>

		<category><![CDATA[Visiongain]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/visongains-report-predicts-that-medical-biobanking-market-will-reach-191-bllion-dollars-in-2015-54826/</guid>
		<description><![CDATA[LONDON, December 14, 2011  -
www.visiongain.com/Report/734/Biobanking-for-Medicine-Technology-and-Market-2012-2022

A new report by visiongain, a London-based business information company, predicts that world medical biobanking revenues will reach $19.1bn in 2015. That market generated $9.0bn in 2010, according to Biobanking for Medicine: Technology and Market 2012-2022, published in December 2011.
The market for medical biobanking technologies and services has expanded rapidly. ... <a href="http://pr.gaeatimes.com/visongains-report-predicts-that-medical-biobanking-market-will-reach-191-bllion-dollars-in-2015-54826/">Original article on  : Visongain&#8217;s Report Predicts That Medical Biobanking Market Will Reach 19.1 Bllion Dollars in 2015</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/visongains-report-predicts-that-medical-biobanking-market-will-reach-191-bllion-dollars-in-2015-54826/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Bright Light Therapy via Ear Canals Improved Reaction Times of Top Athletes in a Placebo-Controlled Psycho-Motoric Study</title>
		<link>http://pr.gaeatimes.com/bright-light-therapy-via-ear-canals-improved-reaction-times-of-top-athletes-in-a-placebo-controlled-psycho-motoric-study-54832/</link>
		<comments>http://pr.gaeatimes.com/bright-light-therapy-via-ear-canals-improved-reaction-times-of-top-athletes-in-a-placebo-controlled-psycho-motoric-study-54832/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Valkee</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Sports]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[finland]]></category>

		<category><![CDATA[Helsinki]]></category>

		<category><![CDATA[Valkee]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/bright-light-therapy-via-ear-canals-improved-reaction-times-of-top-athletes-in-a-placebo-controlled-psycho-motoric-study-54832/</guid>
		<description><![CDATA[HELSINKI, December 14, 2011  -
A placebo controlled study involving top ice hockey players from the Finnish national league has shown motoric reaction times reduced by one fifth in players using the Valkee bright light headset. In the treatment group, the athletes were given 12 minutes of bright light via the ear canal each morning  [..] <a href="http://pr.gaeatimes.com/bright-light-therapy-via-ear-canals-improved-reaction-times-of-top-athletes-in-a-placebo-controlled-psycho-motoric-study-54832/">Read the original article: here</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/bright-light-therapy-via-ear-canals-improved-reaction-times-of-top-athletes-in-a-placebo-controlled-psycho-motoric-study-54832/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Scientific Evidence: More Active Office Environments Pay Off</title>
		<link>http://pr.gaeatimes.com/scientific-evidence-more-active-office-environments-pay-off-54836/</link>
		<comments>http://pr.gaeatimes.com/scientific-evidence-more-active-office-environments-pay-off-54836/#comments</comments>
		<pubDate>Wed, 14 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Wilkhahn Wilkening Hahne Gmbhco.kg</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Consumer Products]]></category>

		<category><![CDATA[Furniture and Furnishings]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Office Products]]></category>

		<category><![CDATA[Surveys / Polls / Research]]></category>

		<category><![CDATA[Bad Muender]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[Germany]]></category>

		<category><![CDATA[Wilkhahn Wilkening + Hahne Gmbh+co.kg]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/scientific-evidence-more-active-office-environments-pay-off-54836/</guid>
		<description><![CDATA[BAD MUENDER, Germany, December 14, 2011  -

Millions of office workers lead too static lives, only moving to operate the keyboard and mouse. However, this causes metabolic dysfunction, muscle atrophy and frequently back pain. Research shows that particularly frequent, varied and small movements are very healthy. Naturally flexible office chairs, encouraging movement in sedentary office ... <a href="http://pr.gaeatimes.com/scientific-evidence-more-active-office-environments-pay-off-54836/" title="Scientific Evidence: More Active Office Environments Pay Off">Read more &raquo;&raquo;</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/scientific-evidence-more-active-office-environments-pay-off-54836/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery</title>
		<link>http://pr.gaeatimes.com/edoxaban-significantly-reduces-risk-of-venous-thromboembolism-by-half-compared-to-enoxaparin-in-japanese-and-taiwanese-patients-following-knee-or-hip-arthroplasty-surgery-54715/</link>
		<comments>http://pr.gaeatimes.com/edoxaban-significantly-reduces-risk-of-venous-thromboembolism-by-half-compared-to-enoxaparin-in-japanese-and-taiwanese-patients-following-knee-or-hip-arthroplasty-surgery-54715/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Daiichi Sankyo Company Limited</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Daiichi Sankyo Company Limited]]></category>

		<category><![CDATA[December 13]]></category>

		<category><![CDATA[December 14]]></category>

		<category><![CDATA[Germany]]></category>

		<category><![CDATA[Japan]]></category>

		<category><![CDATA[Munich]]></category>

		<category><![CDATA[taiwan]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/edoxaban-significantly-reduces-risk-of-venous-thromboembolism-by-half-compared-to-enoxaparin-in-japanese-and-taiwanese-patients-following-knee-or-hip-arthroplasty-surgery-54715/</guid>
		<description><![CDATA[MUNICH, December 14, 2011  -

Pooled results of the STARS E-III and STARS J-V studies presented at the 2011 American Society of Hematology (ASH) Annual Meeting
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the results of a pooled analysis showing that edoxaban*, a direct oral once-daily factor Xa inhibitor, significantly reduced the risk of developing venous thromboembolism (VTE) ... <a href="http://pr.gaeatimes.com/edoxaban-significantly-reduces-risk-of-venous-thromboembolism-by-half-compared-to-enoxaparin-in-japanese-and-taiwanese-patients-following-knee-or-hip-arthroplasty-surgery-54715/">Read : Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/edoxaban-significantly-reduces-risk-of-venous-thromboembolism-by-half-compared-to-enoxaparin-in-japanese-and-taiwanese-patients-following-knee-or-hip-arthroplasty-surgery-54715/feed/</wfw:commentRss>
		</item>
		<item>
		<title>The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics</title>
		<link>http://pr.gaeatimes.com/the-pharmabiotic-research-institute-pri-is-preparing-to-publish-its-first-works-on-the-therapeutic-and-medicinal-potential-of-probiotics-54722/</link>
		<comments>http://pr.gaeatimes.com/the-pharmabiotic-research-institute-pri-is-preparing-to-publish-its-first-works-on-the-therapeutic-and-medicinal-potential-of-probiotics-54722/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>The Pharmabiotic Research Institute pri</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Surveys / Polls / Research]]></category>

		<category><![CDATA[December 13]]></category>

		<category><![CDATA[France]]></category>

		<category><![CDATA[Paris]]></category>

		<category><![CDATA[The Pharmabiotic Research Institute (pri)]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/the-pharmabiotic-research-institute-pri-is-preparing-to-publish-its-first-works-on-the-therapeutic-and-medicinal-potential-of-probiotics-54722/</guid>
		<description><![CDATA[PARIS, December 13, 2011  -
- The Pharmabiotic Research Institute (PRI) brings together industrial and academic players in the area of probiotics research. It is a unique scientific and regulatory association in Europe.

- The PRI asserts that, beyond their traditional food processing applications, probiotics can also be active pharmacological constituents with preventive and curative potential. ... <a href="http://pr.gaeatimes.com/the-pharmabiotic-research-institute-pri-is-preparing-to-publish-its-first-works-on-the-therapeutic-and-medicinal-potential-of-probiotics-54722/" title="The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics">Read more &raquo;&raquo;</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/the-pharmabiotic-research-institute-pri-is-preparing-to-publish-its-first-works-on-the-therapeutic-and-medicinal-potential-of-probiotics-54722/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Merck Serono Helps Eliminate Schistosomiasis in Africa</title>
		<link>http://pr.gaeatimes.com/merck-serono-helps-eliminate-schistosomiasis-in-africa-54730/</link>
		<comments>http://pr.gaeatimes.com/merck-serono-helps-eliminate-schistosomiasis-in-africa-54730/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Merck Serono S A</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Education]]></category>

		<category><![CDATA[Foreign Policy / International Affairs]]></category>

		<category><![CDATA[Government and Policy]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Infectious Disease Control]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Not For Profit]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Africa]]></category>

		<category><![CDATA[December 13]]></category>

		<category><![CDATA[Geneva]]></category>

		<category><![CDATA[Merck Serono S A]]></category>

		<category><![CDATA[Switzerland]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/merck-serono-helps-eliminate-schistosomiasis-in-africa-54730/</guid>
		<description><![CDATA[GENEVA, December 13, 2011  -

Number of donated tablets doubled to around 50 million per year


Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced its intention to further boost its efforts in the fight against the tropical disease schistosomiasis and to continue until the disease has been officially eliminated in Africa. The company plans .... Original source &nbsp;: <a href="http://pr.gaeatimes.com/merck-serono-helps-eliminate-schistosomiasis-in-africa-54730/">Merck Serono Helps Eliminate Schistosomiasis in Africa</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/merck-serono-helps-eliminate-schistosomiasis-in-africa-54730/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Pharmalink AB Gains Exclusive Licence to Archimedes Pharma&#8217;s TARGIT® Technology for Nefecon® (PL-56) Program</title>
		<link>http://pr.gaeatimes.com/pharmalink-ab-gains-exclusive-licence-to-archimedes-pharmas-targit%c2%ae-technology-for-nefecon%c2%ae-pl-56-program-54731/</link>
		<comments>http://pr.gaeatimes.com/pharmalink-ab-gains-exclusive-licence-to-archimedes-pharmas-targit%c2%ae-technology-for-nefecon%c2%ae-pl-56-program-54731/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Pharmalink Ab</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Licensing / Marketing Agreements]]></category>

		<category><![CDATA[New Products / Services]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[December 13]]></category>

		<category><![CDATA[Pharmalink AB]]></category>

		<category><![CDATA[Stockholm]]></category>

		<category><![CDATA[sweden]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/pharmalink-ab-gains-exclusive-licence-to-archimedes-pharmas-targit%c2%ae-technology-for-nefecon%c2%ae-pl-56-program-54731/</guid>
		<description><![CDATA[STOCKHOLM, December 13, 2011  -

Pharmalink AB, today announces it has gained an exclusive global license to Archimedes Pharma Ltd.&#8217;s TARGIT® drug delivery technology for use in its lead program, Nefecon® for the treatment of the kidney disease IgA nephropathy.
As part of the agreement, Pharmalink has also acquired from Archimedes Pharma certain specialized equipment and .... Source &nbsp;: <a href="http://pr.gaeatimes.com/pharmalink-ab-gains-exclusive-licence-to-archimedes-pharmas-targit%c2%ae-technology-for-nefecon%c2%ae-pl-56-program-54731/" title="Pharmalink AB Gains Exclusive Licence to Archimedes Pharma&#8217;s TARGIT® Technology for Nefecon® (PL-56) Program">Gaea News Network</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/pharmalink-ab-gains-exclusive-licence-to-archimedes-pharmas-targit%c2%ae-technology-for-nefecon%c2%ae-pl-56-program-54731/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting</title>
		<link>http://pr.gaeatimes.com/pieris-presents-preclinical-data-for-prs-080-hepcidin-antagonist-anticalinr-program-at-ash-annual-meeting-54742/</link>
		<comments>http://pr.gaeatimes.com/pieris-presents-preclinical-data-for-prs-080-hepcidin-antagonist-anticalinr-program-at-ash-annual-meeting-54742/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Pieris Ag</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Medical Equipment]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[california]]></category>

		<category><![CDATA[December 13]]></category>

		<category><![CDATA[Pieris AG]]></category>

		<category><![CDATA[San diego]]></category>

		<category><![CDATA[United States of America]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/pieris-presents-preclinical-data-for-prs-080-hepcidin-antagonist-anticalinr-program-at-ash-annual-meeting-54742/</guid>
		<description><![CDATA[SAN DIEGO, California, December 13, 2011  -

&#8211; Breadth of Pharmacokinetic Data Points to Tunable Half-life for Platform &#8211;
Pieris AG presented novel preclinical in vitro and in vivo data for its PRS-080 Anticalin hepcidin antagonist in an oral presentation at the American Society of Hematology Annual Meeting, the company announced today.  In a presentation entitled ... <a href="http://pr.gaeatimes.com/pieris-presents-preclinical-data-for-prs-080-hepcidin-antagonist-anticalinr-program-at-ash-annual-meeting-54742/">Read the original article on Gaea Times at  : Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/pieris-presents-preclinical-data-for-prs-080-hepcidin-antagonist-anticalinr-program-at-ash-annual-meeting-54742/feed/</wfw:commentRss>
		</item>
		<item>
		<title>ResearchMoz: Optimizing Treatment for Bone Metastases in Patients With Advanced Cancers</title>
		<link>http://pr.gaeatimes.com/researchmoz-optimizing-treatment-for-bone-metastases-in-patients-with-advanced-cancers-54745/</link>
		<comments>http://pr.gaeatimes.com/researchmoz-optimizing-treatment-for-bone-metastases-in-patients-with-advanced-cancers-54745/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Researchmoz</dc:creator>
		
		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Surveys / Polls / Research]]></category>

		<category><![CDATA[December 13]]></category>

		<category><![CDATA[New York]]></category>

		<category><![CDATA[Researchmoz]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/researchmoz-optimizing-treatment-for-bone-metastases-in-patients-with-advanced-cancers-54745/</guid>
		<description><![CDATA[NEW YORK, December 13, 2011  -
New Report Added in ResearchMoz Reports Database Optimizing Treatment for Bone Metastases in Patients with Advanced Cancers Published by  Assessment Group.

Understand current practice patterns related to bone metastases in patients with advanced cancers. Patient specific unfolding case scenarios presented to 174 high-prescribing oncologists on the treatment of bones metastases in patients with ... <a href="http://pr.gaeatimes.com/researchmoz-optimizing-treatment-for-bone-metastases-in-patients-with-advanced-cancers-54745/">Read : ResearchMoz: Optimizing Treatment for Bone Metastases in Patients With Advanced Cancers</a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/researchmoz-optimizing-treatment-for-bone-metastases-in-patients-with-advanced-cancers-54745/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Sweet Success for Hosmac India Pvt. Ltd. at  ET NOW-IndiaMART Leaders of Tomorrow Awards 2011</title>
		<link>http://pr.gaeatimes.com/sweet-success-for-hosmac-india-pvt-ltd-at-et-now-indiamart-leaders-of-tomorrow-awards-2011-54747/</link>
		<comments>http://pr.gaeatimes.com/sweet-success-for-hosmac-india-pvt-ltd-at-et-now-indiamart-leaders-of-tomorrow-awards-2011-54747/#comments</comments>
		<pubDate>Tue, 13 Dec 2011 05:00:00 +0000</pubDate>
		<dc:creator>Indiamart.com</dc:creator>
		
		<category><![CDATA[Awards]]></category>

		<category><![CDATA[Banking and Financial Services]]></category>

		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Business]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[December 13]]></category>

		<category><![CDATA[India]]></category>

		<category><![CDATA[IndiaMART.com]]></category>

		<category><![CDATA[New delhi]]></category>

		<guid isPermaLink="false">http://pr.gaeatimes.com/sweet-success-for-hosmac-india-pvt-ltd-at-et-now-indiamart-leaders-of-tomorrow-awards-2011-54747/</guid>
		<description><![CDATA[NEW DELHI, December 13, 2011  -



Dr. Vivek Desai, MD, Hosmac India Pvt. Ltd. receives award from Mr. NR Narayana Murthy, Chairman Emeritus, Infosys Technologies
Clear winner under Healthcare &#38; Biotech Category

With another feather of appreciation added to his hat of success at the felicitation ceremony of &#8216;ET NOW-IndiaMART Leaders of Tomorrow Awards 2011&#8242;, Dr. Vivek ... <a href="http://pr.gaeatimes.com/sweet-success-for-hosmac-india-pvt-ltd-at-et-now-indiamart-leaders-of-tomorrow-awards-2011-54747/" title="Sweet Success for Hosmac India Pvt. Ltd. at  ET NOW-IndiaMART Leaders of Tomorrow Awards 2011">Read more >></a>.]]></description>
		<wfw:commentRss>http://pr.gaeatimes.com/sweet-success-for-hosmac-india-pvt-ltd-at-et-now-indiamart-leaders-of-tomorrow-awards-2011-54747/feed/</wfw:commentRss>
		</item>
	</channel>
</rss>

